dc.contributor.author |
Chira, Sergiu
|
|
dc.contributor.author |
Jackson, Carlo Stephan
|
|
dc.contributor.author |
Oprea, Iulian
|
|
dc.contributor.author |
Ozturk, Ferhat
|
|
dc.contributor.author |
Pepper, Michael Sean
|
|
dc.contributor.author |
Diaconu, Iulia
|
|
dc.contributor.author |
Braicu, Cornelia
|
|
dc.contributor.author |
Raduly, Lajos-Zsolt
|
|
dc.contributor.author |
Calin, George A.
|
|
dc.contributor.author |
Berindan-Neagoe, Ioana
|
|
dc.date.accessioned |
2016-05-05T10:58:47Z |
|
dc.date.available |
2016-05-05T10:58:47Z |
|
dc.date.issued |
2015-09-15 |
|
dc.description.abstract |
The emergence of genetic engineering at the beginning of the 1970′s opened the
era of biomedical technologies, which aims to improve human health using genetic
manipulation techniques in a clinical context. Gene therapy represents an innovating
and appealing strategy for treatment of human diseases, which utilizes vehicles or
vectors for delivering therapeutic genes into the patients’ body. However, a few
past unsuccessful events that negatively marked the beginning of gene therapy
resulted in the need for further studies regarding the design and biology of gene
therapy vectors, so that this innovating treatment approach can successfully move
from bench to bedside. In this paper, we review the major gene delivery vectors
and recent improvements made in their design meant to overcome the issues that
commonly arise with the use of gene therapy vectors. At the end of the manuscript,
we summarized the main advantages and disadvantages of common gene therapy
vectors and we discuss possible future directions for potential therapeutic vectors. |
en_ZA |
dc.description.department |
Immunology |
en_ZA |
dc.description.librarian |
am2016 |
en_ZA |
dc.description.sponsorship |
This work is part of research grant No. 128/2014; PNII-
PT-PCCA-2013-4-2166 “New strategies for improving
life quality and survival in cancer patients: molecular and
clinical studies of the tumor genome in deuterium-depleted
water treatment augmentation - GenCanD”. Dr Calin is
The Alan M. Gewirtz Leukemia & Lymphoma Society
Scholar. Work in Dr. Calin’s laboratory is supported in
part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01
CA182905-01, the UT MD Anderson Cancer Center SPORE
in Melanoma grant from NCI (P50 CA093459), Aim at
Melanoma Foundation and the Miriam and Jim Mulva
research funds, the Brain SPORE (2P50CA127001), the
Center for Radiation Oncology Research Project, the Center
for Cancer Epigenetics Pilot project, a 2014 Knowledge
GAP MDACC grant, a CLL Moonshot pilot project, the UT
MD Anderson Cancer Center Duncan Family Institute for
Cancer Prevention and Risk Assessment, a SINF grant in
colon cancer, the Laura and John Arnold Foundation, the
RGK Foundation and the Estate of C. G. Johnson, Jr,. |
en_ZA |
dc.description.uri |
http://www.impactjournals.com/oncotarget |
en_ZA |
dc.identifier.citation |
Chira, S, Jackson, CS, Oprea, I, Ozturk, F, Pepper, MS, Diaconu, I, Braicu, C, Raduly, L-Z, Calin, GA & Berindan-Neagoe, I 2015, 'Progresses towards safe and efficient gene therapy vectors', Oncotarget, vol. 6, no. 321, pp. 30675-30703. |
en_ZA |
dc.identifier.issn |
1949-2553 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/52471 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Impact Journals |
en_ZA |
dc.rights |
Copyright: [Authors] et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License. |
en_ZA |
dc.subject |
Biomedical technologies |
en_ZA |
dc.subject |
Gene therapy |
en_ZA |
dc.subject |
Human diseases |
en_ZA |
dc.subject |
Patients’ body |
en_ZA |
dc.title |
Progresses towards safe and efficient gene therapy vectors |
en_ZA |
dc.type |
Article |
en_ZA |